Physical examination during chemoradiation predicts outcome of locally advanced head and neck cancer. Secondary results of a randomized phase III trial (SAKK 10/94)

Oral Oncology ◽  
2013 ◽  
Vol 49 (10) ◽  
pp. 1006-1009
Author(s):  
Pirus Ghadjar ◽  
Hong Sun ◽  
Frank Zimmermann ◽  
Stephan Bodis ◽  
Jacques Bernier ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Physical Examination ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Phase Iii ◽  
Advanced Head ◽  
Phase Iii Trial ◽  
Secondary Results

scholarly journals Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer

2013 ◽  
Vol 54 (6) ◽  
pp. 1110-1117 ◽  
Author(s):  
Imjai Chitapanarux ◽  
Ekkasit Tharavichitkul ◽  
Pimkhuan Kamnerdsupaphon ◽  
Nantaka Pukanhapan ◽  
Roy Vongtama
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Concurrent Chemoradiotherapy ◽  
Locally Advanced ◽  
Phase Iii ◽  
Advanced Head ◽  
Phase Iii Trial

Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer

2005 ◽  
Vol 23 (34) ◽  
pp. 8636-8645 ◽  
Author(s):  
Ricardo Hitt ◽  
Antonio López-Pousa ◽  
Javier Martínez-Trufero ◽  
Vicente Escrig ◽  
Joan Carles ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Continuous Infusion ◽  
Induction Chemotherapy ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Phase Iii ◽  
Rank Test ◽  
Advanced Head ◽  
Log Rank Test

Purpose To compare the antitumor activity and toxicity of the two induction chemotherapy treatments of paclitaxel, cisplatin, and fluorouracil (FU; PCF) versus standard cisplatin and FU (CF), both followed by chemoradiotherapy (CRT), in locally advanced head and neck cancer (HNC). Patients and Methods Eligibility criteria included biopsy-proven, previously untreated, stage III or IV locally advanced HNC. Patients received either CF (cisplatin 100 mg/m2 on day 1 plus FU 1,000 mg/m2 continuous infusion on days 1 through 5) or PCF (paclitaxel 175 mg/m2 on day 1, cisplatin 100 mg/m2 on day 2, and FU 500 mg/m2 continuous infusion on days 2 through 6); both regimens were administered for three cycles every 21 days. Patients with complete response (CR) or partial response of greater than 80% in primary tumor received additional CRT (cisplatin 100 mg/m2 on days 1, 22, and 43 plus 70 Gy). Results A total of 382 eligible patients were randomly assigned to CF (n = 193) or PCF (n = 189). The CR rate was 14% in the CF arm v 33% in the PCF arm (P < .001). Median time to treatment failure was 12 months in the CF arm compared with 20 months in the PCF arm (log-rank test, P = .006; Tarone-Ware, P = .003). PCF patients had a trend to longer overall survival (OS; 37 months in CF arm v 43 months in PCF arm; log-rank test, P = .06; Tarone-Ware, P = .03). This difference was more evident in patients with unresectable disease (OS: 26 months in CF arm v 36 months in PCF arm; log-rank test, P = .04; Tarone-Ware, P = .03). CF patients had a higher occurrence of grade 2 to 4 mucositis than PCF patients (53% v 16%, respectively; P < .001). Conclusion Induction chemotherapy with PCF was better tolerated and resulted in a higher CR rate than CF. However, new trials that compare induction chemotherapy plus CRT versus CRT alone are needed to better define the role of neoadjuvant treatment.

Sign in / Sign up

Export Citation Format

Share Document